Filana Therapeutics, Inc.
FLNA
Last
$0.82
Day
+0.4%
1y
+203300.0%
5y
+80.8%
52w
-64.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1132d
EMA 21
0.85
EMA 50
0.89
EMA 200
0.85
20d high
-37.4%
5y high
-64.1%
5y range
36th
Positions held
Your positionsFLNA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
3
Hold
watch
Signal
Neutral
Target
$1.06
Stop
$0.61
Stop distance
25.3%
Target vs last
+29.8%
Fundamentals
| Market cap | $39.30M | Enterprise value | -$43.38M | Trailing P/E | — | Forward P/E | — |
| PEG | 1.62 | Price / book | 0.62 | Beta | -0.66 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -55.8% | ROA | -7.1% | Debt / equity | — |
| Current ratio | 2.09 | Free cash flow | $3.98M | Analyst recommendation | none | Mean target | $6.50 |
| 52w high | $4.98 | 52w low | $0.67 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$8.6M | -$10.3M | -$12.5M | -$10.8M | -$44.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.4M | -$11.2M | -$14.3M | -$11.9M | -$45.4M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$91.0M | -$24.3M | -$97.2M | -$76.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$96.1M | -$142M | -$107M | -$81.5M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Filana Therapeutics Insider Bought Shares Worth $278,132, According to a Recent SEC Filing
2026-09-22 · BC-Most Active Stocks
2026-09-22 · Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy
2026-07-29 · Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update
Price (daily)
Full chart · RSI · MACD · patternsFLNA · daily-21.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin